Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

American Journal of Medicine

Volumn 106, Issue 6, 1999, Pages 629-635

  Wallis, Diane E ^a   Workman, Diane L ^a   Lewis, Bruce E ^b   Steen, Lowell ^b   Pifarre, Roque ^b   Moran, John F ^b  

^a Midwest Heart Specialists   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033029056     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00124-2     Document Type: Article

References (44)

1. Warkentin T.E., Hayward C.P., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity an explanation for the thrombotic complications of heparin-induced thrombocytopenia . Blood. 84:1994;3691-3699.
2. Cines D.B., Tomaski A., Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. NEJM. 316:1987;581-589.
3. Chong B.H. Heparin-induced thrombocytopenia. Br J Haematol. 89:1995;431-439.
4. Laster J., Cikrit D., Walker N., Silver D. The heparin-induced thrombocytopenia syndrome an update . Surgery. 102:1987;763-770.
5. King D.J., Kelton J.G. Heparin-associated thrombocytopenia. Ann Intern Med. 100:1984;535-540.
6. Dryjski M., Dryjski H. Heparin induced thrombocytopenia. Eur J Vasc Endovasc Surg. 11:1996;260-269.
7. Brieger D.B., Mak K.H., Kottke-Marchant K, Topol E.J. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 31:1998;1449-1459.
8. Singer R.L., Mannion J.D., Bauer T.L., Armenti F.R., Edie R.N. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest. 104:1993;1436-1440.
9. Warkentin T.E., Kelton J.G. Heparin-induced thrombocytopenia. Prog Hemost Thromb. 10:1991;1-34.
10. Silver D., Kapsch D.N., Tsoi E.K. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Ann Surg. 198:1983;301-306.
11. Walls J.T., Curtis J.J., Silver D., Boley T.M., Schmaltz R.A., Nawarawong W. Heparin-induced thrombocytopenia in open heart surgical patients sequelae of late recognition . Ann Thorac Surg. 53:1992;787-791.
12. Cines D.B., Kaywin P., Bina M., Tomaski A., Schreiber A.D. Heparin-associated thrombocytopenia. NEJM. 303:1980;788-795.
13. Zucker M.B., Katz I.R. Platelet factor 4 production, structure, and physiologic and immunologic action . Proc Soc Exp Biol Med. 198:1991;693-702.
14. Laster J.L., Nichols W.K., Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern Med. 149:1989;2285-2287.
15. Rama B.N., Haake R.E., Bander S.J., Ghasem-Zadeh A., Gorla C. Heparin-flush associated thrombocytopenia-induced hemorrhage a case report . Nebr Med J. 76:1991;392-394.
16. Warkentin T.E., Kelton J.S. Heparin and platelets. Hematol/Oncol Clin North Am. 4:1990;243-264.
17. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. NEJM. 332:1995;1330-1335.
18. Chong B.H. Heparin-induced thrombocytopenia. Aust N Z J Med. 22:1992;145-152.
19. Almeida J.I., Coats R., Liem T.K., Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg. 27:1998;309-314.
20. Amiral J., Marfaing-Koka A, Wolf M., et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 88:1996;410-416.
21. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 101:1996;502-507.
22. Phelen B.K. Heparin-associated thrombosis without thrombocytopenia. Ann Intern Med. 99:1983;637-638.
23. Hach-Wunderle V., Kainer K., Krug B., Müller-Berghaus G., Pötzsch B. Heparin-associated thrombosis despite normal platelet counts. Lancet. 344:1994;469-470.
24. Bauer T.L., Arepally G., Konkle B.A., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 95:1997;1242-1246.
25. Baughman R.P., Lower E.E., Flessa H.C., Tollerud D.J. Thrombocytopenia in the intensive care unit. Chest. 104:1993;1243-1247.
26. Kelton J.G., Warkentin T.E. Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination. Am J Clin Path. 104:1995;611-613.
27. Kluft C., Verheijen J.H., Jie A.F., et al. The postoperative fibrinolytic shutdown a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma . Scand J Clin Lab Invest. 45:1985;605-610.
28. Boshkov L.K., Warkentin T.E., Hayward C.P., Andrew M., Kelton J.G. Heparin-induced thrombocytopenia and thrombosis clinical and laboratory studies . Br J Haematol. 84:1993;322-328.
29. Krishnamurti C., Alving B.M. Plasminogen activator inhibitor-1 biochemistry and evidence for modulation of fibrinolysis in vivo . Semin Thromb Hemost. 18:1992;67-80.
30. Suh J.S., Malik M.I., Aster R.H., Visentin G.P. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 54:1997;196-201.
31. Smith A.J., Holt R.E., Fitzpatrick J.B., et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J. 131:1996;434-439.
32. Granger C.B., Miller J.M., Bovill E.G., et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 91:1995;1929-1935.
33. Chong B.H., Pitney W.R., Castaldi P.A. Heparin-induced thrombocytopenia association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation . Lancet. 2:1982;1246-1249.
34. Gruel Y., Rupin A., Watier H., Vigier S., Bardos P., Leroy J. Anticardiolipin antibodies in heparin-associated thrombocytopenia. Thromb Res. 67:1992;601-606.
35. Burgess J.K., Lindeman R., Chesterman C.N., Chong B.H. Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol. 91:1995;761-766.
36. Warkentin T.E., Hayward C.P., Smith C.A., Kelly P.M., Kelton J.G. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 120:1992;371-379.
37. Myllyla G. Aggregation of human blood platelets by immune complexes in the sedimentation pattern test. Scand J Haematol. 19:(suppl):1973;1-56.
38. Chong B.H., Pilgrim R.L., Cooley M.A., Chesterman C.N. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood. 81:1993;988-993.
39. Leclerc J.R., Gent M., Hirsh J., et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin a multi-institutional cohort study in patients who underwent hip or knee arthroplasty . Arch Intern Med. 158:1998;873-878.
40. Hirsh J., Warkentin T.E., Raschke R., Granger C., Ohman E.M., Dalen J.E. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest. 114:(suppl):1998;489S-510S.
41. Lewis B.E., Walenga J.M., Wallis D.E. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Haemost. 23:1997;197-202.
42. Greinacher A., Völpel H., Janssens U., et al. Recombinant hiruden (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia a prospective study . Circulation. 99:1999;73-80.
43. Jeske W.P., Walenga J.M., Szatkowski E., et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res. 88:1997;271-281.
44. Walenga J.M., Wallis D.E., Lewis B.E., Leja F., Bakhos M., Fareed J. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost. 25:1999;77-81.